Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Phil on +44 1494 818040 or phil@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Phil Hardy
Senior Account Manager
phil@zenopa.com
+44 1494 818040

Testimonials
I was interviewed and contacted promptly with regular job roles, not only was I contacted but the follow through I had been missing from other agencies was there from the beginning of the process.
Danielle, 2011

Bayer HealthCare reports positive regorafenib trial data

4 April 2012 00:00 in Pharmaceutical Company Product News


Bayer HealthCare has published positive new clinical trial data supporting the efficacy of its new drug regorafenib for the treatment of gastrointestinal stromal tumours (GIST).

Results from the phase III Grid trial showed that Bayer's treatment was able to significantly improve progression-free survival rates among patients with metastatic or unresectable GIST who have been unable to benefit from prior therapy.

It was able to meet its primary efficacy endpoint in the study while also demonstrating safety and tolerability performance in line with expectations.

Data from this study will be used to support regulatory applications for regorafenib in this specification, while the drug is also in development as a metastatic colorectal cancer therapy.

Dr Kemal Malik, head of global development and Bayer HealthCare executive committee member, said: "These findings may represent important progress in this difficult-to-treat disease with high unmet patient need."

Last week, the company also published clinical data from a new phase III study of Xarelto, showing its efficacy among pulmonary embolism patients.ADNFCR-8000103-ID-801333584-ADNFCR

Other news stories from 04/04/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd